BSECompany UpdateResults14h ago
Natco Pharma Ltd
Q2FY27 Earnings Conference Call Transcript
Natco Pharma Ltd's Q2FY27 earnings conference call transcript has been released, showing a 28.4% increase in consolidated total revenues to ₹1,019.4 crores, driven by strong performance in international formulation business. EBITDA including other income stood at ₹310 crores, with EBITDA margin of 30.4%. Consolidated profit after tax was ₹202.6 crores. The company acquired an additional 13.25% stake in associate company Adcock Ingram Holding Limited, taking its total holdings to 49%. Domestic formulation business revenue stood at ₹145 crores, with Brazil business revenue growing 66%.
BSECompany UpdateMgmt Change2d ago
Natco Pharma Ltd
Intimation of Investor Meet
Natco Pharma Ltd has announced an investor meet on November 19, 2026, in Pune, where company officials will interact with investors. The meeting schedule is subject to change due to exigencies. No unpublished price-sensitive information will be discussed during the interactions.
BSECompany UpdateResults4d ago
Natco Pharma Ltd
Newspaper publication for Unaudited Financail Results for the Qaurter and Half year ended September 30, 2026 and Record date for the 2nd Interim Dividend for the FY ending 2026-27
Natco Pharma Ltd has published unaudited financial results for the quarter and half year ended September 30, 2026, and announced a record date for the 2nd interim dividend for the FY ending 2026-27.
BSEResult▲ PositiveResults5d ago
Natco Pharma Ltd
Un audited Financial Results for the quarter and half year ended 30th September, 2026
Natco Pharma Ltd has announced unaudited financial results for the quarter and half year ended September 30, 2026, with a profit before tax of Rs. 2,432 crore and a profit for the period of Rs. 2,026 crore. The company has also declared a second interim dividend of Rs. 1.25 per equity share. The results show a decline in profit before tax and profit for the period compared to the same period last year.
BSECorp. Action▲ PositiveDividend5d ago
Natco Pharma Ltd
19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27
Natco Pharma Ltd declares 2nd interim dividend of Rs.1.25 per equity share for FY 2026-27, with a record date of 19th November, 2026.
BSEBoard Meeting▲ PositiveResults5d ago
Natco Pharma Ltd
Outcome of Board Meeting
Natco Pharma Ltd has announced unaudited financial results for the quarter and half year ended September 30, 2026, along with the declaration of a second interim dividend of Rs. 1.25 per equity share. The company has also provided a consolidated balance sheet as of September 30, 2026.
BSEInsider Trading / SASTPledge4 Nov 2026
Natco Pharma Ltd
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 04, 2026 for V C Nannapaneni
Natco Pharma Ltd's promoter V.C. Nannapaneni has created a pledge of 8,50,000 equity shares for the purpose of subscribing to the company's Rights Issue.
BSEInsider Trading / SASTResults30 Oct 2026
Natco Pharma Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Venkaiah Chowdary Nannapaneni
Natco Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the allotment of equity shares through a rights issue to eligible equity shareholders. The disclosure includes details of the promoters and members of the promoter group who have acquired shares through the allotment.
BSEBoard MeetingResults29 Oct 2026
Natco Pharma Ltd
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the Un-audited Financial Results for the Quarter ended 30th September, 2026 and declaration of Second Interim Dividend, if any
Natco Pharma Ltd has scheduled a Board Meeting on 13/11/2026 to consider unaudited financial results for Q2 FY 2026-27 and declare second interim dividend, if any.
BSECompany UpdateFundraise29 Oct 2026
Natco Pharma Ltd
News Paper Publication for Basis of Allotment of Right Issue
Natco Pharma Ltd has published the basis of allotment of its rights issue in newspapers as per SEBI regulations.
BSECompany UpdateFundraise23 Oct 2026
Natco Pharma Ltd
Outcome of the Fund-raising Committee meeting approving the allotment of 17058082 Equity shares
Natco Pharma Ltd has announced the allotment of 1,70,58,082 Equity Shares at ₹750 per Equity Share, as part of its Rights Issue, increasing its paid-up equity share capital from ₹35,82,19,740 to ₹39,23,35,904.
BSEInsider Trading / SAST22 Oct 2026
Natco Pharma Ltd
Update on Trading Window Closure period
Natco Pharma Ltd has closed its trading window for all directors, designated persons, and connected individuals from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026. The trading window will reopen from October 23, 2026, to October 28, 2026, to enable the credit of rights equity shares in demat accounts of allottees.
BSECompany UpdateFundraise22 Oct 2026
Natco Pharma Ltd
Intimation of closure of the Issue period of the Rights Issue of NATCO Pharma Limited (the "Company")
Natco Pharma Ltd has announced the closure of its Rights Issue, which opened on October 12, 2026, and will close on October 22, 2026. The issue aims to raise up to Rs.12,794 million through the issuance of equity shares at Rs.750 each.
BSECompany Update▲ PositiveOrder Win19 Oct 2026
Natco Pharma Ltd
Natco Pharma announces launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market
Natco Pharma Ltd has launched Carboplatin Injection, a generic version of Paraplatin, in the U.S. market through its U.S. subsidiary NATCO Pharma USA LLC, in collaboration with Teyro Labs Pvt Ltd.
BSECompany UpdateRegulatory16 Oct 2026
Natco Pharma Ltd
Compliance Certificate under Reg.74(5) of SEBI(DP) Regulations, 2018
Natco Pharma Ltd has issued a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming the dematerialization of securities and updating the records of the company.
BSEInsider Trading / SASTPromoter Reclassif.13 Oct 2026
Natco Pharma Ltd
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 12, 2026 for V C Nannapaneni
Natco Pharma Ltd has made a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a potential change in control or significant stake acquisition.
BSECompany UpdateFundraise7 Oct 2026
Natco Pharma Ltd
News Paper Publications
Natco Pharma Ltd has published newspaper notices regarding its forthcoming Rights Issue in Financial Express, Surya, and Janasatta on October 7, 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
BSEAGM/EGMMgmt Change30 Sept 2026
Natco Pharma Ltd
Evoting Results along with Scrutinizer Report for the 43rd Annual General Meeting held on 30/09/2026
Natco Pharma Ltd has announced the voting results of its 43rd Annual General Meeting, with all resolutions passed with high voting percentages. The company has also announced the re-appointment of a director and the ratification of the remuneration of cost auditors. Additionally, the company has sought shareholder approval for raising funds up to Rs. 2,000 crores through various means.
BSEInsider Trading / SASTMgmt Change30 Sept 2026
Natco Pharma Ltd
Closure of Trading Window
Natco Pharma Ltd has announced the closure of its trading window for directors, designated persons, and their relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending September 30, 2026.
BSEAGM/EGMResults30 Sept 2026
Natco Pharma Ltd
Proceedings of the 43rd Annual General Meting
Natco Pharma Ltd held its 43rd Annual General Meeting on September 30, 2026, through video conference. The meeting was attended by 51 members, and the company's Chairman and Managing Director, V.C. Nannapaneni, conducted the proceedings. The meeting approved the audited annual financial statements for FY 2025-26, confirmed three interim dividends, and re-appointed a director. The company also announced plans to raise up to ₹2,000 crores through various methods.